← All trials
NCT03781804
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 27, 2018
- Primary completion
- Dec 31, 2020
- Completion date
- Dec 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 378
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- OptiNose ASLead sponsor
- OptiNose ASStudy chair
- OptiNose ASStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.